<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1667">
  <stage>Registered</stage>
  <submitdate>24/08/2007</submitdate>
  <approvaldate>24/08/2007</approvaldate>
  <nctid>NCT00521066</nctid>
  <trial_identification>
    <studytitle>GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse</studytitle>
    <scientifictitle>A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Pelvic Organ Prolapse</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>300-06-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pelvic Organ Prolapse</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - GYNECARE PROSIMA* Pelvic Floor Repair System

1 - Prosima Pelvic Floor Repair System


Treatment: devices: GYNECARE PROSIMA* Pelvic Floor Repair System
procedure for pelvic organ prolapse

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Success based on overall POP-Q score at 12 months post-procedure. - Success is determined by achievement of an overall POP-Q score of ICS Stage =1, without further re-intervention for POP.</outcome>
      <timepoint>12-months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Success based on overall POP-Q score at 24 months post-procedure. - Success is determined by achievement of an overall POP-Q score of ICS Stage =1, without further re-intervention for POP</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Success based on treated compartment ICS POP-Q stage - Success will be determined by achievement of treated compartment POP-Q score of ICS Stage =1, without further re-intervention for POP.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Success based on treated compartment ICS POP-Q stage - Success will be determined by achievement of treated compartment POP-Q score of ICS Stage =1, without further re-intervention for POP.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Success defined as the leading edge within the hymen - Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Success defined as the leading edge within the hymen - Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean PFDI-20 score</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean PFDI-20 score</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in PFDI-20 scores</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in PFDI-20 scores</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean POPDI score - POPDI is a sub score of PFDI-20</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean POPDI score - POPDI is a sub score of PFDI-20</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in POPDI score - POPDI is a sub scores of PFDI-20</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in POPDI score - POPDI is a sub score of PFDI-20</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean CRADI score - CRADI is a sub score of PFDI-20</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean CRADI score - CRADI is a sub score of PFDI-20</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in CRADI score - CRADI is a sub score of PFDI-20</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in CRADI score - CRADI is a sub score of PFDI-20</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean UDI score - UDI is a sub score of PFDI-20</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean UDI score - UDI is a sub score of PFDI-20</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in UDI score - UDI is a sub score of PFDI-20</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in UDI score - UDI is a sub score of PFDI-20</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EuroQol (EQ-5D health state) change from baseline</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EuroQol (EQ-5D health state) change from baseline</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean PFIQ-7 score</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean PFIQ-7 score</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in PFIQ-7 score</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in PFIQ-7 score</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean POPIQ score - POPIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean POPIQ score - POPIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in POPIQ score - POPIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in POPIQ score - POPIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean CRAIQ score - CRAIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean CRAIQ score - CRAIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in CRAIQ score - CRAIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in CRAIQ score - CRAIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean UIQ score - UIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean UIQ score - UIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in UIQ score - UIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in UIQ score - UIQ is a sub-score of PFIQ-7</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean PISQ-12 score - In subjects sexually active at baseline, assessment of sexual function</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean PISQ-12 score - In subjects sexually active at baseline, assessment of sexual function</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in PISQ-12 score - In subjects sexually active at baseline, assessment of sexual function</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in PISQ-12 score - In subjects sexually active at baseline, assessment of sexual function</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia</outcome>
      <timepoint>ongoing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of procedure - From time to first incision to time of last suture used to secure VSD</outcome>
      <timepoint>perioperative</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain score measured using Visual Analog Scale (VAS).</outcome>
      <timepoint>24 hours post surgery and at the 3-4 week visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Discomfort of balloon removal, measured using VAS at time of removal.</outcome>
      <timepoint>24 hrs post-surgical</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject perception of VSD: Awareness - Measured by visual analogue scale</outcome>
      <timepoint>3-4 week visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject perception of VSD: Discomfort - Measured by visual analogue scale</outcome>
      <timepoint>3-4 week visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject perception of VSD: Acceptability of discharge - Measured by visual analogue scale</outcome>
      <timepoint>3-4 week visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject global impression - assessed on a 5 point Likert scale</outcome>
      <timepoint>12 month visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject global impression - assessed on a 5 point Likert scale</outcome>
      <timepoint>24 month visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III,
             suitable for surgical repair. Vaginal hysterectomy, perineal repair and/or mid
             urethral sling procedures for incontinence may be performed concurrently.

          -  Age = 18 years.

          -  Agrees to participate in the study, including completion of all study-related
             procedures, evaluations and questionnaires, and documents this agreement by signing
             the Ethics Committee / IRB approved informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Additional surgical intervention concurrent to the PROSIMA procedure (e.g.
             sacrocolpopexy, paravaginal repair, tubal sterilisation).

          -  Previous repair of pelvic organ prolapse involving insertion of mesh.

          -  Previous hysterectomy within 6 months of scheduled surgery.

          -  Experimental drug or experimental medical device within 3 months prior to the planned
             procedure.

          -  Active genital, urinary or systemic infection at the time of the surgical procedure.
             Surgery may be delayed in such subjects until the infection is cleared.

          -  Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.

          -  History of chemotherapy or pelvic radiation therapy.

          -  Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease,
             multiple sclerosis, spina bifida, spinal cord injury or trauma).

          -  Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis,
             endometriosis, coccydynia, vulvodynia).

          -  Nursing or pregnant or intends future pregnancy.

          -  In the investigator's opinion, any medical condition or psychiatric illness that could
             potentially be life threatening or affect their ability to complete the study visits
             according to this protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>150</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Women's Hospital - Melbourne</hospital>
    <postcode>3053 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tubingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ethicon, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to is to evaluate the success of the GYNECARE PROSIMA* system in
      women with symptoms for pelvic organ prolapse (POP) requiring surgical correction of POP.

      (*TRADEMARK)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00521066</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Robinson, M.D.</name>
      <address>Ethicon, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>